secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2021-12-15T23:59:59+00:00
Accession:  0001193125-21-357380
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly raises 2021 revenue guidance to $28.0B-$28.3B; 2022 EPS seen at $8.00-$8.15
--------------------------------------------------------------------------------

- 2021 revenue guidance raised to $28.0B-$28.3B (from $27.2B-$27.6B); non-GAAP EPS raised to $8.15-$8.20.
- 2022 revenue guidance $27.8B-$28.3B; reported EPS $8.00-$8.15; non-GAAP EPS $8.50-$8.65.
- Initiated rolling FDA submission for pirtobrutinib in MCL; completion in 2022, regulatory action early 2023.
- Plans new phase 3 studies for tirzepatide in obesity outcomes, sleep apnea, and kidney disease; donanemab biomarker data disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000119312521357380/0001193125-21-357380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000119312521357380/d212746d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-357380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer